NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW) Short Interest Down 83.1% in May

NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW) was the recipient of a significant decrease in short interest in the month of May. As of May 15th, there was short interest totaling 5,154 shares, a decrease of 83.1% from the April 30th total of 30,482 shares. Based on an average trading volume of 45,351 shares, the short-interest ratio is presently 0.1 days.

NRx Pharmaceuticals Price Performance

Shares of NASDAQ NRXPW remained flat at $0.00 during mid-day trading on Friday. The stock had a trading volume of 176,260 shares, compared to its average volume of 33,307. The firm’s 50 day simple moving average is $0.01 and its two-hundred day simple moving average is $0.04. NRx Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $0.18.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for neuropsychiatric and neurodegenerative disorders. The company’s research pipeline includes small‐molecule candidates designed to address underlying pathophysiological mechanisms implicated in conditions such as Rett syndrome, Alzheimer’s disease and Long COVID. Leveraging a proprietary formulation and delivery approach, NRx seeks to advance compounds that have demonstrated safety in prior studies toward new indications with significant unmet medical need.

Among its lead programs, NRx is developing NP-120 (sarizotan) for the treatment of Rett syndrome, a rare genetic disorder that impacts brain development in young girls.